Suven completes phase I dose study on new drug

Hyderabad, Sept. 29 Suven Life Sciences Ltd announced on Monday that it has completed the Phase-I single ascending dose study of SUVN-502 in healthy subjects.

Pfizer drops glaucoma drug study in Asia

DMRC completes work of third tunnel in phase 2 project

Suven LifeSciences

Ranbaxy plans trials for new drug

Orchid gets USFDA nod for non-antibiotic drug

Magic Mushroom Study finds long benefit in illegal mushroom drug

Now, Ranbaxy AIDS drug under US lens

This entry was posted on Monday, September 29th, 2008 at 7:13 pm and is filed under Indian Stock Market News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

Indian Stock Market

Suven completes phase I dose study on new drug

Leave a Reply

Categories

Archives

Feed

Links

Subscribe by E-Mail :

Recent Posts

Recent Comments

Indian Stock Market News